Therefore,.nless questioned directly, they generally do not volunteer information about their use of these medications. If your child wears contact lenses and has conjunctivitis, your doctor or eye doctor may recommend that the contact lenses not be worn until the infection is gone. Throw away any make-up used while infected. Sometimes pink eye appears after a cold or a sore throat . Your doctor may recommend allergy shots, administered over several months, to reduce your sensitivity to the allergen. It may help if you clean the area around your eyes gently and remove any secretions from your eyelids and lashes with cotton wool soaked in warm water. Patients with gonorrhoeal infections, neonates with infections, and patients who are immunocompromised should be admitted for administration of intravenous antibiotics. Am J Ophthalmol. 1989;107:511–4. 7. FREE PREVIEW. Cultures should be obtained in certain patients, including young children and debilitated persons. It also can spread through coughing and sneezing. no dataHis special interests include contact lenses, nutrition and preventive vision care. Patients with suspected ocular heretic infection should be referred to an ophthalmologist.
We wanted to provide our potential patients and investors with a clear snapshot of the numerous cannabinoid-based therapeutic products that we currently have undergoing clinical trials and when these products are anticipated to be on the market and approved by the FDA and EMA, said AXIM Biotechnologies, Inc.s Chief Executive Officer George E. Anastassov, MD, DDS, MBA. Our company is continuing to develop cannabinoid-based drugs to find answers for health conditions with currently no known sustainable answers. View the product pipeline chart here. An AXIM Biotech breakthrough invention on pace to be fully registered by the EMA and FDA by the end of 2018 is the worlds first patented cannabinoid controlled-release chewing gum: MedChew Rx. Recently featured by Reuters global news agency, MedChew Rx will change the way that medicine is delivered to patients worldwide. Directly compared to a sublingually delivered cannabis-based product currently on the market for multiple sclerosis (MS) in the Reuters article, the potential economic impact for MedChew Rx is estimated at $4.8 billion USD for spasticity and pain associated with MS. http://experteyedoctor.denaliinstitute.org/2016/11/04/practical-guidance-on-effective-eye-surgery-strategies/AXIMs pipeline of intellectual property (IP) protected cannabinoid-based products include: MedChew Rx – THC/CBD cannabinoid controlled-release functional chewing gum to address pain and muscle spasticity in multiple sclerosis (MS) patients as well as numerous indication extensions based on the proprietary delivery platform RENECANN – the worlds first cannabigerol (CBG)-based skincare product line ORAXIMAX – the worlds first CBG-based oral care product line Suppocann – a suppository cannabinoid-release product for GI conditions such as IBD, IBS and Crohns disease Ophthocann and Cannbleph – cannabinoid-based products for reduction of intraocular pressure and for relief of conjunctivitis About AXIM AXIM Biotechnologies, Inc. ( AXIM ) is an innovative biotechnology Company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com .
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/axim-biotechnologies-inc-publishes-product-130000510.html